Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Director | June 05, 2026 | June 08, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, Chief Commercial Officer | February 28, 2020 | February 29, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director · President and CEO | January 29, 2026 | April 21, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | September 23, 2026 | September 25, 2026 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | June 11, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-04 | Direct | 40,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
Sarepta Therapeutics, Inc.
Report date February 28, 2020 · Filed February 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,567 |
Reported balance
After 2020-02-28 transaction · row 1
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 6,700 · Balance 8,567 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.47 · Expires 2030-02-28 | Direct | 37,500 |
Reported balance
After 2020-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-28 · Grant · Acquired 37,500 · Balance 37,500 F2: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy grantor retained annuity trust | 3,441 |
Reported balance
Holding disclosure · report date 2020-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,441 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date.
F2: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.
Solid Biosciences Inc.
Report date January 29, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 169,401 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 169,401 · Balance 169,401 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Stoke Therapeutics, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.11 · Expires 2036-09-22 | Direct | 39,674 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 39,674 · Balance 39,674 F1: The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.
Vor Biopharma Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-10 | Direct | 56,345 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 56,345 · Balance 56,345 F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ra Pharmaceuticals, Inc.
Report date April 02, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.88 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.99 · Expires 2028-11-14 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Verve Therapeutics, Inc.
Report date July 25, 2025 · Filed July 28, 2025
Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-25 · Disposition to issuer · Disposed 136,139 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-25 · Disposition to issuer · Disposed 42,200 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the
F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 20:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 39,674 | $0.00 Strike: $26.11 | $0.00 |
DisclosureSEC source: 0001685994-26-000009 · form4-09252026_080935.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,674 Underlying: Common Stock · 39,674 shares Expires 2036-09-22 F1 · derivative.exercise_date: The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 13, 2026 00:40 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock option (right to buy) · Derivative | 56,345 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-269997 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,345 Underlying: Common Stock · 56,345 shares Expires 2036-06-10 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 18:34 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262281 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 02:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 16,644 | $5.82 | $96,923.01 |
DisclosureSEC source: 0001193125-26-057878 · ownership.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,405 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 30,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057878 · ownership.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,063 Underlying: Common Stock · 30,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 30,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057878 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 252,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 48,913 | $6.44 | $315,092.65 |
DisclosureSEC source: 0001193125-26-041519 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,018 F1 · shares: This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 80,258 | $6.44 | $516,612.72 |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,931 F3 · shares: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 100,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · derivative · entry 7 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,200 Underlying: Common Stock · 100,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. F8 · derivative.exercise_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 401,600 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary. F8 · derivative.expiration_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 401,600 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 100,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 254,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · derivative · entry 6 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,900 Underlying: Common Stock · 254,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. F7 · derivative.exercise_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. F7 · derivative.expiration_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 509,850 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · derivative · entry 5 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 509,850 Underlying: Common Stock · 509,850 shares Expires 2036-01-29 F6 · derivative.exercise_date: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionPerformance Stock Units · Derivative | 169,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · derivative · entry 4 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. F5 · derivative.exercise_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. F5 · derivative.expiration_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 169,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034087 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Apr 21, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 169,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-166735 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,401 Underlying: Common Stock · 169,401 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · derivative.exercise_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. F2 · derivative.expiration_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 10,808 | $5.11 | $55,228.88 |
DisclosureSEC source: 0001193125-25-308115 · ownership.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,388 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 28,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-308115 · ownership.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,613 Underlying: Common Stock · 28,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 28,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308115 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · balance_after: Includes 2,866 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 168,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-109723 · ownership.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. F1 · derivative.expiration_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:10 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 337,500 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0000950170-25-109723 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,500 Underlying: Common Stock · 337,500 shares Expires 2035-08-14 F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 17:15 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | Disposition to issuerStock Option (right to buy) · Derivative | 42,200 | Not disclosed Strike: $5.73 | Not disclosed |
DisclosureSEC source: 0000950170-25-099251 · ownership.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,200 shares Expires not disclosed F1 · price: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2 · price: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). F1 · derivative.exercise_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2 · derivative.exercise_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2 · derivative.expiration_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 17:15 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | Disposition to issuerStock Option (right to buy) · Derivative | 136,139 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0000950170-25-099251 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136,139 shares Expires not disclosed F1 · price: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2 · price: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). F1 · derivative.exercise_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2 · derivative.exercise_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2 · derivative.expiration_date: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 21:14 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001415889-25-020022 · form4-07182025_090703.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-07-15 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option shall vest and become exercisable on August 16, 2025 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 17:01 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 42,200 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0000950170-25-083234 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,200 Underlying: Common Stock · 42,200 shares Expires 2035-06-04 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 16:11 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082324 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 16:19 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000950170-25-048549 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-03-27 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from March 28, 2025 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,365 | $3.96 | $45,005.40 |
DisclosureSEC source: 0000950170-25-022200 · ownership.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,717 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 30,031 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-022200 · ownership.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,094 Underlying: Common Stock · 30,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 30,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-022200 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| January 31, 2025 Filed Feb 11, 2025 21:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 401,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017959 · ownership.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401,600 Underlying: Common Stock · 401,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:27 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,114 | $5.60 | $62,236.18 |
DisclosureSEC source: 0000950170-24-133360 · ownership.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,484 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Mr. Cumbo. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:27 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 28,612 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133360 · ownership.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,225 Underlying: Common Stock · 28,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:27 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 28,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-133360 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · balance_after: Includes 3,547 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 07:45 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 136,139 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000950170-24-078783 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,139 Underlying: Common Stock · 136,139 shares Expires 2034-06-25 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 17:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 120,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016219 · ownership.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,125 Underlying: Common Stock · 120,125 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 17:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 240,250 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0000950170-24-016219 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,250 Underlying: Common Stock · 240,250 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 19:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,757 | $2.77 | $32,516.33 |
DisclosureSEC source: 0000950170-23-068076 · ownership.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,439 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 28,612 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068076 · ownership.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,837 Underlying: Common Stock · 28,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 28,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-068076 · ownership.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 17:00 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 26,642 | $0.00 Strike: $19.84 | $0.00 |
DisclosureSEC source: 0001209191-23-038471 · doc4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,642 Underlying: Common Stock · 26,642 shares Expires 2033-06-14 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 114,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037681 · doc4.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,449 Underlying: Common Stock · 114,449 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 228,900 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-22-037681 · doc4.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,900 Underlying: Common Stock · 228,900 shares Expires 2032-12-02 F2 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-037681 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584 F1 · price: The reporting person acquired 584 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:00 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $14.04 | $0.00 |
DisclosureSEC source: 0001209191-22-036370 · doc4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal monthly installments through June 9, 2025, subject to the Reporting Person's continued service. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 09:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.99 | $0.00 |
DisclosureSEC source: 0001104659-20-042768 · a4.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-11-14 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 09:01 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.88 | $0.00 |
DisclosureSEC source: 0001104659-20-042768 · a4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · shares: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014226 · doc4.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014226 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,567 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 26,084 | $0.00 Strike: $26.24 | $0.00 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · derivative · entry 9 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,881 Underlying: Common Stock · 26,084 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 3,895 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · derivative · entry 8 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,895 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.